Education
About Us
Working with TipRanks
Follow Us
Kura Oncology (DE:KUR)
:KUR
Total Valuation
Kura Oncology has a market cap or net worth of €749.59M. The enterprise value is €245.46M.
Market Cap€749.59M
Enterprise Value€245.46M
Share Statistics
Kura Oncology has 87,017,520 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding87,017,520
Owned by Insiders1.83%
Owned by Institutions1.75%
Financial Efficiency
Kura Oncology’s return on equity (ROE) is -0.42 and return on invested capital (ROIC) is -28.50%.
Return on Equity (ROE)-0.42
Return on Assets (ROA)-0.23
Return on Invested Capital (ROIC)-28.50%
Return on Capital Employed (ROCE)-0.28
Revenue Per Employee280.64K
Profits Per Employee-906.16K
Employee Count192
Asset Turnover0.07
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Kura Oncology is ―. Kura Oncology’s PEG ratio is 1.50.
PE Ratio―
PS Ratio13.93
PB Ratio1.81
Price to Fair Value1.81
Price to FCF5.61
Price to Operating Cash Flow10.11
PEG Ratio1.50
Income Statement
In the last 12 months, Kura Oncology had revenue of 53.88M and earned -173.98M in profits. Earnings per share was -2.02.
Revenue53.88M
Gross Profit53.03M
Operating Income-193.19M
Pretax Income-171.97M
Net Income-173.98M
EBITDA-169.50M
Earnings Per Share (EPS)-2.02
Cash Flow
In the last 12 months, operating cash flow was 87.80M and capital expenditures -4.69M, giving a free cash flow of 83.11M billion.
Operating Cash Flow87.80M
Free Cash Flow83.11M
Free Cash Flow per Share0.96
Dividends & Yields
Kura Oncology pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.90
52-Week Price Change-48.59%
50-Day Moving Average7.71
200-Day Moving Average6.41
Relative Strength Index (RSI)51.62
Average Volume (3m)182.00
Important Dates
Kura Oncology upcoming earnings date is Mar 3, 2026, After Close (Confirmed).
Last Earnings DateNov 4, 2025
Next Earnings DateMar 3, 2026
Ex-Dividend Date―
Financial Position
Kura Oncology as a current ratio of 9.46, with Debt / Equity ratio of 5.83%
Current Ratio9.46
Quick Ratio9.46
Debt to Market Cap0.01
Net Debt to EBITDA1.23
Interest Coverage Ratio-119.33
Taxes
In the past 12 months, Kura Oncology has paid 2.02M in taxes.
Income Tax2.02M
Effective Tax Rate-0.01
Enterprise Valuation
Kura Oncology EV to EBITDA ratio is -3.20, with an EV/FCF ratio of 4.05.
EV to Sales10.07
EV to EBITDA-3.20
EV to Free Cash Flow4.05
EV to Operating Cash Flow4.04
Balance Sheet
Kura Oncology has €549.66M in cash and marketable securities with €14.13M in debt, giving a net cash position of €535.53M billion.
Cash & Marketable Securities€549.66M
Total Debt€14.13M
Net Cash€535.53M
Net Cash Per Share€6.15
Tangible Book Value Per Share€4.80
Margins
Gross margin is 79.86%, with operating margin of -358.55%, and net profit margin of -322.89%.
Gross Margin79.86%
Operating Margin-358.55%
Pretax Margin-319.15%
Net Profit Margin-322.89%
EBITDA Margin-314.57%
EBIT Margin-316.14%
Analyst Forecast
The average price target for Kura Oncology is €22.72, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target€22.72
Price Target Upside171.80% Upside
Analyst ConsensusStrong Buy
Analyst Count13
Revenue Growth Forecast―
EPS Growth Forecast―